{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:14:31Z","timestamp":1791465271323,"version":"4.3.4"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:00:00Z","timestamp":1719964800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.bioorg.2024.107602","type":"journal-article","created":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T07:00:04Z","timestamp":1719558004000},"page":"107602","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Density functional theory and enzyme studies support interactions between angiotensin receptor blockers and angiotensin converting enzyme-2: Relevance to coronavirus 2019"],"prefix":"10.1016","volume":"150","author":[{"given":"Vasso","family":"Apostolopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikitas","family":"Georgiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demeter","family":"Tzeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Mavromoustakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham J.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Kelaidonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minos-Timotheos","family":"Matsoukas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotirios","family":"Tsiodras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Swiderski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Kate Gadanec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Zulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos T.","family":"Chasapis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Matsoukas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.bioorg.2024.107602_b0005","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/emmm.201000080","article-title":"Angiotensin II revisited: new roles in inflammation, immunology and aging","volume":"2","author":"Benigni","year":"2010","journal-title":"EMBO Mol. Med."},{"issue":"7","key":"10.1016\/j.bioorg.2024.107602_b0010","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1161\/ATVBAHA.118.311282","article-title":"Renin-angiotensin system and cardiovascular functions","volume":"38","author":"Wu","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107602_b0015","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1152\/physrev.00023.2016","article-title":"The ACE2\/angiotensin-(1\u20137)\/MAS axis of the renin-angiotensin system: focus on angiotensin-(1\u20137)","volume":"98","author":"Santos","year":"2018","journal-title":"Physiol. Rev."},{"issue":"44","key":"10.1016\/j.bioorg.2024.107602_b0020","article-title":"Relationship between ACE2 and other components of the renin-angiotensin system","volume":"22","author":"Cohen","year":"2020","journal-title":"Curr. Hypertens. Rep."},{"issue":"11","key":"10.1016\/j.bioorg.2024.107602_b0025","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.2174\/1389450117666160727142401","article-title":"The anti-inflammatory potential of ACE2\/angiotensin-(1\u20137)\/Mas receptor axis: evidence from basic and clinical research","volume":"18","author":"Rodrigues Prestes","year":"2017","journal-title":"Curr. Drug Targets"},{"issue":"3","key":"10.1016\/j.bioorg.2024.107602_b0030","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/bph.12159","article-title":"ACE2, angiotensin-(1\u20137) and Mas receptor axis in inflammation and fibrosis","volume":"169","author":"Simoes e Silva","year":"2013","journal-title":"Br. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.bioorg.2024.107602_b0035","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1161\/01.HYP.0000146400.57221.74","article-title":"Upregulation of angiotensin-converting enzyme 2 by all-trans retinoic acid in spontaneously hypertensive rats","volume":"44","author":"Zhong","year":"2004","journal-title":"Hypertension"},{"issue":"6891","key":"10.1016\/j.bioorg.2024.107602_b0040","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nature00786","article-title":"Angiotensin-converting enzyme 2 is an essential regulator of heart function","volume":"417","author":"Crackower","year":"2002","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.bioorg.2024.107602_b0045","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1172\/JCI16980","article-title":"Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice","volume":"116","author":"Gurley","year":"2006","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.bioorg.2024.107602_b0050","doi-asserted-by":"crossref","first-page":"L1020","DOI":"10.1152\/ajplung.00097.2020","article-title":"Covid-19 infection and mortality: a physiologist's perspective enlightening clinical features and plausible interventional strategies","volume":"318","author":"Abassi","year":"2020","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"issue":"7","key":"10.1016\/j.bioorg.2024.107602_b0055","doi-asserted-by":"crossref","first-page":"e016219","DOI":"10.1161\/JAHA.120.016219","volume":"9","author":"Guo","year":"2020","journal-title":"J. Am. Heart Assoc."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107602_b0060","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1038\/s41467-020-18319-6","article-title":"Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor","volume":"11","author":"Yang","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2024.107602_b0065","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.bbrc.2021.08.040","article-title":"A model for COVID-19-induced dysregulation of ACE2 shedding by ADAM17","volume":"573","author":"Healy","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107602_b0070","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.pharmthera.2010.06.003","article-title":"Trilogy of ACE2: a peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters","volume":"128","author":"Kuba","year":"2010","journal-title":"Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.bioorg.2024.107602_b0075","doi-asserted-by":"crossref","DOI":"10.3390\/biom13050787","article-title":"Role of angiotensin II in cardiovascular diseases: introducing bisartans as a novel therapy for coronavirus 2019","volume":"13","author":"Swiderski","year":"2023","journal-title":"Biomolecules"},{"issue":"2","key":"10.1016\/j.bioorg.2024.107602_b0080","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/cvr\/cvac130","article-title":"Addressing global disparities in blood pressure control: perspectives of the International Society of Hypertension","volume":"119","author":"Schutte","year":"2023","journal-title":"Cardiovasc. Res."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107602_b0085","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1021\/acs.jcim.1c01126","article-title":"Discovery of bile acid derivatives as potent ACE2 activators by virtual screening and essential dynamics","volume":"62","author":"Fiorillo","year":"2022","journal-title":"J. Chem. Inf. Model."},{"issue":"47","key":"10.1016\/j.bioorg.2024.107602_b0090","doi-asserted-by":"crossref","first-page":"13982","DOI":"10.1021\/acs.jafc.0c05064","article-title":"Quercetin and Its metabolites inhibit recombinant human angiotensin-converting enzyme 2 (ACE2) activity","volume":"68","author":"Liu","year":"2020","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.bioorg.2024.107602_b0095","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.phrs.2017.07.026","article-title":"Antihypertensive drugs","volume":"124","author":"Laurent","year":"2017","journal-title":"Pharmacol. Res."},{"issue":"10","key":"10.1016\/j.bioorg.2024.107602_b0100","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1021\/jm980499w","article-title":"An effort to understand the molecular basis of hypertension through the study of conformational analysis of losartan and sarmesin using a combination of nuclear magnetic resonance spectroscopy and theoretical calculations","volume":"42","author":"Mavromoustakos","year":"1999","journal-title":"J. Med. Chem."},{"issue":"10229","key":"10.1016\/j.bioorg.2024.107602_b0105","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bioorg.2024.107602_b0110","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.120.15143","article-title":"Effects of angiotensin II receptor blockers and ACE (angiotensin-converting enzyme) inhibitors on virus infection, inflammatory status, and clinical outcomes in patients with COVID-19 and hypertension","volume":"76","author":"Yang","year":"2020","journal-title":"Hypertension"},{"issue":"12","key":"10.1016\/j.bioorg.2024.107602_b0115","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1161\/CIRCRESAHA.120.317134","article-title":"Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19","volume":"126","author":"Zhang","year":"2020","journal-title":"Circ. Res."},{"issue":"15","key":"10.1016\/j.bioorg.2024.107602_b0120","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27154854","article-title":"Actions of novel angiotensin receptor blocking drugs, bisartans, relevant for COVID-19 therapy: biased agonism at angiotensin receptors and the beneficial effects of neprilysin in the renin angiotensin system","volume":"27","author":"Moore","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2024.107602_b0125","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.csbj.2022.04.010","article-title":"Discovery of a new generation of angiotensin receptor blocking drugs: receptor mechanisms and in silico binding to enzymes relevant to SARS-CoV-2","volume":"20","author":"Ridgway","year":"2022","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.bioorg.2024.107602_b0130","doi-asserted-by":"crossref","unstructured":"H. Ridgway, G.J. Moore, L.K. Gadanec, A. Zulli, V. Apostolopoulos, W. Hoffmann, K. W\u0119grzyn, N. Vassilaki, G. Mpekoulis, M. Zouridakis, Novel benzimidazole angiotensin receptor blockers with anti-SARS-CoV-2 activity equipotent to that of nirmatrelvir: computational and enzymatic studies, Expert Opin. Therap. Targets (just-accepted) (2024).","DOI":"10.1080\/14728222.2024.2362675"},{"issue":"2011","key":"10.1016\/j.bioorg.2024.107602_b0135","first-page":"20120488","article-title":"Density functional theory across chemistry, physics and biology","volume":"372","author":"van Mourik","year":"2014","journal-title":"Philos. Trans. A Math. Phys. Eng. Sci."},{"issue":"7","key":"10.1016\/j.bioorg.2024.107602_b0140","doi-asserted-by":"crossref","DOI":"10.3390\/biom11070979","article-title":"Receptor interactions of angiotensin II and angiotensin receptor blockers-relevance to COVID-19","volume":"11","author":"Moore","year":"2021","journal-title":"Biomolecules"},{"key":"#cr-split#-10.1016\/j.bioorg.2024.107602_b0145.1","unstructured":"M. Frisch, G. Trucks, H. Schlegel, G. Scuseria, M. Robb, J. Cheeseman, J. Montgomery Jr, T. Vreven, K. Kudin, J. Burant, Gaussian, Inc., Wallingford, CT, 2004"},{"key":"#cr-split#-10.1016\/j.bioorg.2024.107602_b0145.2","doi-asserted-by":"crossref","unstructured":"C. Lee, W. Yang, RG Parr, Phys. Rev. B 37 (1988) 785.","DOI":"10.1103\/PhysRevB.37.785"},{"issue":"3","key":"10.1016\/j.bioorg.2024.107602_b0150","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1063\/1.462066","article-title":"Density-functional thermochemistry. I. The effect of the exchange-only gradient correction","volume":"96","author":"Becke","year":"1992","journal-title":"J. Chem. Phys."},{"issue":"2","key":"10.1016\/j.bioorg.2024.107602_b0155","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1021\/ct700248k","article-title":"Performance of B3LYP density functional methods for a large set of organic molecules","volume":"4","author":"Tirado-Rives","year":"2008","journal-title":"J. Chem. Theory Comput."},{"issue":"5","key":"10.1016\/j.bioorg.2024.107602_b0160","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1021\/cr9903205","article-title":"Conceptual and computational DFT in the study of aromaticity","volume":"101","author":"De Proft","year":"2001","journal-title":"Chem. Rev."},{"issue":"9","key":"10.1016\/j.bioorg.2024.107602_b0165","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1002\/qua.21901","article-title":"Are the Hirshfeld and Mulliken population analysis schemes consistent with chemical intuition?","volume":"109","author":"Saha","year":"2009","journal-title":"Int. J. Quantum Chem."},{"issue":"8","key":"10.1016\/j.bioorg.2024.107602_b0170","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1021\/cr9904009","article-title":"Quantum mechanical continuum solvation models","volume":"105","author":"Tomasi","year":"2005","journal-title":"Chem. Rev."},{"key":"10.1016\/j.bioorg.2024.107602_b0175","unstructured":"G. RA, 1, mj frisch, gw trucks, hb schlegel, ge scuseria, ma robb, jr cheeseman, g. Scalmani, v. Barone, b. Mennucci, ga petersson et al., gaussian, Inc, Wallingford CT 121 (2009) 150\u2013166."},{"issue":"45","key":"10.1016\/j.bioorg.2024.107602_b0180","doi-asserted-by":"crossref","first-page":"13185","DOI":"10.1021\/bi035268s","article-title":"Angiotensin-converting enzyme-2 (ACE2): comparative modeling of the active site, specificity requirements, and chloride dependence","volume":"42","author":"Guy","year":"2003","journal-title":"Biochemistry"},{"issue":"Pt 1","key":"10.1016\/j.bioorg.2024.107602_b0185","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1042\/BJ20040634","article-title":"Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism","volume":"383","author":"Rice","year":"2004","journal-title":"Biochem. J."},{"key":"10.1016\/j.bioorg.2024.107602_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2020.170477","article-title":"Metabolism of angiotensin peptides by angiotensin converting enzyme 2 (ACE2) and analysis of the effect of excess zinc on ACE2 enzymatic activity","volume":"137","author":"Polak","year":"2021","journal-title":"Peptides"},{"key":"10.1016\/j.bioorg.2024.107602_b0195","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.csbj.2022.04.010","article-title":"Discovery of a new generation of angiotensin receptor blocking drugs: Receptor mechanisms and in silico binding to enzymes relevant to SARS-CoV-2","volume":"20","author":"Ridgway","year":"2022","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"15","key":"10.1016\/j.bioorg.2024.107602_b0200","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.3390\/molecules27154854","article-title":"Actions of novel angiotensin receptor blocking drugs, bisartans, relevant for COVID-19 therapy: biased agonism at angiotensin receptors and the beneficial effects of neprilysin in the renin angiotensin system","volume":"27","author":"Moore","year":"2022","journal-title":"Molecules"},{"issue":"9","key":"10.1016\/j.bioorg.2024.107602_b0205","doi-asserted-by":"crossref","first-page":"8454","DOI":"10.3390\/ijms24098454","article-title":"Computational and enzymatic studies of sartans in SARS-CoV-2 spike RBD-ACE2 Binding: the role of tetrazole and perspectives as antihypertensive and COVID-19 therapeutics","volume":"24","author":"Kelaidonis","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.bioorg.2024.107602_b0210","doi-asserted-by":"crossref","first-page":"787","DOI":"10.3390\/biom13050787","article-title":"Role of angiotensin II in cardiovascular diseases: introducing bisartans as a novel therapy for coronavirus 2019","volume":"13","author":"Swiderski","year":"2023","journal-title":"Biomolecules"},{"issue":"5","key":"10.1016\/j.bioorg.2024.107602_b0215","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.3390\/v14051029","article-title":"Understanding the driving forces that trigger mutations in SARS-CoV-2: mutational energetics and the role of arginine blockers in COVID-19 therapy","volume":"14","author":"Ridgway","year":"2022","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/j.bioorg.2024.107602_b0220","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3390\/v15020309","article-title":"Molecular epidemiology of SARS-CoV-2: the dominant role of arginine in mutations and infectivity","volume":"15","author":"Ridgway","year":"2023","journal-title":"Viruses"},{"issue":"18","key":"10.1016\/j.bioorg.2024.107602_b0225","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1021\/jm950690v","article-title":"Synthesis and contractile activities of cyclic thrombin receptor-derived peptide analogues with a Phe-Leu-Leu-Arg motif: importance of the Phe\/Arg relative conformation and the primary amino group for activity","volume":"39","author":"Matsoukas","year":"1996","journal-title":"J. Med. Chem."},{"issue":"10229","key":"10.1016\/j.bioorg.2024.107602_b0230","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.bioorg.2024.107602_b0235","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1111\/j.1742-4658.2005.04756.x","article-title":"Identification of critical active-site residues in angiotensin-converting enzyme-2 (ACE2) by site-directed mutagenesis","volume":"272","author":"Guy","year":"2005","journal-title":"FEBS J."},{"issue":"40","key":"10.1016\/j.bioorg.2024.107602_b0240","doi-asserted-by":"crossref","first-page":"11852","DOI":"10.1021\/ja0277226","article-title":"Substrate-based design of the first class of angiotensin-converting enzyme-related carboxypeptidase (ACE2) inhibitors","volume":"124","author":"Dales","year":"2002","journal-title":"J. Am. Chem. Soc."},{"issue":"12","key":"10.1016\/j.bioorg.2024.107602_b0245","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/qjmed\/hcz206","article-title":"Angiotensin-converting enzyme 2 attenuates inflammatory response and oxidative stress in hyperoxic lung injury by regulating NF-kappaB and Nrf2 pathways","volume":"112","author":"Fang","year":"2019","journal-title":"QJM"},{"issue":"8","key":"10.1016\/j.bioorg.2024.107602_b0250","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nm1267","article-title":"A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury","volume":"11","author":"Kuba","year":"2005","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.bioorg.2024.107602_b0255","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1161\/HYPERTENSIONAHA.113.01337","article-title":"Diminazene aceturate enhances angiotensin-converting enzyme 2 activity and attenuates ischemia-induced cardiac pathophysiology","volume":"62","author":"Qi","year":"2013","journal-title":"Hypertension"},{"key":"10.1016\/j.bioorg.2024.107602_b0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117749","article-title":"Diminazene aceturate extenuate the renal deleterious consequences of angiotensin-II induced by gamma-irradiation through boosting ACE2 signaling cascade","volume":"253","author":"Hasan","year":"2020","journal-title":"Life Sci."},{"issue":"3","key":"10.1016\/j.bioorg.2024.107602_b0265","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1021\/acsptsci.2c00003","article-title":"Allosteric site of ACE-2 as a drug target for COVID-19","volume":"5","author":"Dutta","year":"2022","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"10","key":"10.1016\/j.bioorg.2024.107602_b0270","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1002\/jmv.25992","article-title":"ACE2 activators for the treatment of COVID 19 patients","volume":"92","author":"Rodriguez-Puertas","year":"2020","journal-title":"J. Med. Virol."},{"issue":"8","key":"10.1016\/j.bioorg.2024.107602_b0275","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1177\/1087057111413919","article-title":"Prediction of off-target effects on angiotensin-converting enzyme 2","volume":"16","author":"Kulemina","year":"2011","journal-title":"J. Biomol. Screen."},{"issue":"5","key":"10.1016\/j.bioorg.2024.107602_b0280","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1161\/HYPERTENSIONAHA.107.108944","article-title":"Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents","volume":"51","author":"Hernandez Prada","year":"2008","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.bioorg.2024.107602_b0285","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1021\/acsptsci.0c00081","article-title":"Potential role of peptide-based antiviral therapy against SARS-CoV-2 infection","volume":"3","author":"Maiti","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"3","key":"10.1016\/j.bioorg.2024.107602_b0290","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jpha.2022.10.005","article-title":"Advances and challenges in using nirmatrelvir and its derivatives against SARS-CoV-2 infection","volume":"13","author":"Chen","year":"2023","journal-title":"J. Pharm. Anal."},{"issue":"6575","key":"10.1016\/j.bioorg.2024.107602_b0295","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.bioorg.2024.107602_b0300","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/cpt.2688","article-title":"Pharmacokinetics of oral nirmatrelvir\/ritonavir, a protease inhibitor for treatment of COVID-19, in subjects with renal impairment","volume":"112","author":"Toussi","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.bioorg.2024.107602_b0305","doi-asserted-by":"crossref","first-page":"E218","DOI":"10.1503\/cmaj.220081","article-title":"Nirmatrelvir-ritonavir for COVID-19","volume":"194","author":"McDonald","year":"2022","journal-title":"CMAJ"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206824005078?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206824005078?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T04:33:52Z","timestamp":1728275632000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206824005078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":62,"alternative-id":["S0045206824005078"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.107602","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Density functional theory and enzyme studies support interactions between angiotensin receptor blockers and angiotensin converting enzyme-2: Relevance to coronavirus 2019","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.107602","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107602"}}